{'fraction_non_alphanumeric': 0.03995680345572354, 'fraction_numerical': 0.01079913606911447, 'mean_word_length': 5.528169014084507, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Two-site immunofluorometric assay for pregnancy-specific beta 1-glycoprotein (SP1).

We describe an immunoassay for human pregnancy-specific beta 1-glycoprotein by use of fluorescein-labeled antibodies to this protein. The technique is generally similar to that of a "two-site" immunoradiometric assay but has the advantage of stability of tracer and avoidance of radiation hazard. However, the procedure requires relatively large quantities of antibody. Furthermore, the within-assay coefficient of variation (11.8%) is greater than that for radioimmunoassay (6.5%). This results from imprecision of the end-point detection, and some inherent difficulties in optimizing a "two-site" immunometric system. Concentrations of endogenous material as measured by the fluorometric assay are 1.9-fold higher than those obtained with radioimmunoassay, probably because the former detects multiple forms of this heterogeneous material.